HCHB and element5 form strategic alliance to accelerate the agentic AI movement in post-acute care

Element5’s Agentic AI platform will be integrated with the HCHB EHR

Mycenax and Spera forge alliance to streamline ADC drug substance

Novo Nordisk’s amylin therapy cagrilintide shows significant weight loss in phase 3 trial

Cagrilintide represents a novel approach to obesity management

FDA approves Corstasis’ bumetanide nasal spray to treat edema in heart, liver, and kidney disease

Galimedix completes phase 1 study with oral small molecule GAL-101

The study further confirmed that GAL-101 effectively crosses the blood-brain barrier

Biocartis receives FDA approval for Idylla CDx MSI test

First fully automated, cartridge-based companion diagnostic test for colorectal cancer patients approved in the United States

Cadila launches nutritional replenisher ‘Nu Nutridac’ capsule

Nu Nutridac is a nutritional replenisher for neurodegenerative and anxiety-related disorders

Zhimeng Biopharma’s investigational drug approved to begin phase 2 epilepsy clinical trial in China

This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis

Kytopen collaborates with BlueWhale Bio for cell therapy manufacturing

Both will develop a non-viral manufacturing workflow designed to eliminate key bottlenecks and accelerate the delivery of lifesaving engineered cell therapies to patients

iRegene Therapeutics secures series B+ financing

NouvNeu001 is the world’s first allogeneic iPSC-derived cell therapy for Parkinson’s disease to receive this designation